Please assess the completion status of the following clinical trial:

Trial Title: Additive Homeopathy in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Clinical diagnosis of advanced tumor stages of non small-cell lung carcinoma (NSCLC) IIIB, IIIC, IV.~Exclusion Criteria:~* sensitizing mutation of the EGFR gene or translocation of the ALK gene~* refusal to sign informed consent~* pregnancy~* hematological, hepatic, or renal pathology~* coronary heart disease~* history of secondary tumor~* major surgery within 4 weeks prior to study entry~* active infection and symptomatic peripheral neuropathy~* central nervous system metastases unless the metastases were treated and stable~* active autoimmune disease~* use of systemic immunosuppressive treatment~* use of systemic treatment during the previous 2 years~* active interstitial lung disease, or a history of pneumonitis for which glucocorticoids were prescribed~* previous systemic therapy for metastatic disease or previous irradiation~* use of any complementary and/or alternative therapy, including homeopathy other than the research treatment during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Additive homeopathy in cancer patients (Type: ACTIVE_COMPARATOR): Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
- Additive homeopathic placebo globules (Type: PLACEBO_COMPARATOR): Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
- No intervention (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).